(α − β − µ 2 ) 2 − 4αµ 2 . However, because information about µ 0 X comes only asymptotically (Meza et al., 2008) , the model is practically unidentifiable. To this end, we assume µ 0 = µ 1 , and parameterize the model as h 3 (t) = r
S1
where r = (µ 0 X) (µ 1 /α).
As parameterized, multiplicative effects on r affect both pre-initiation rates µ 0 and µ 1 . We fix αX = 3 × 10 7 ; the model was insensitive-because of the practical identifiability-to the choice of this combination. In Table S2 , we present the AIC for the three-stage models as well.
Uncertainty quantification
Confidence intervals (95%) for the hazards and period and cohort effects are presented in Figure S5 for the APC-TSCE model with period and cohort effects on initiation. Markov chain Monte Carlo (MCMC) methods were used to estimate covariance matrices for the sixteen parameters for each demographic-site pair: using the likelihood as the density function, a multivariate normal posterior distribution was estimated using the Bhat package in R (v3.1). Seeded by the numerical estimates, we used a burn of 1,000 and a run of 10,000.
APC Results
The residual deviance for each unconstrained APC model with natural spline effects is shown Table S3 for each race-gender pair. We use seven degrees of freedom for age, eight for cohort effects, and five for period, corresponding to approximately one degree of freedom for eight, twelve, and eight years respectively. Comparison of values may be made only down columns, not across rows.
To avoid issues of identifiability, we use the age-cohort model. The age and cohort effects are plotted in Figure Table S1 : Akaike Information Criterion (AIC) for APC-TSCE models of incidence of oral squamous cell carcinomas by race and cancer subsite group relative to the model with both period and cohort effects on r.
Positive values denote worse relative fits. Table S2 : Akaike Information Criterion (AIC) for APC-3SCE models of incidence of oral squamous cell carcinomas by race and cancer subsite group relative to the APC-TSCE model with both period and cohort effects on r.
S3
Positive values denote worse relative fits.
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